Long-term results of the S.M.A.R.T. Control™ stent for superficial femoral artery lesions, J-SMART Registry

Circulation Journal

Volumn 75, Issue 4, 2011, Pages 939-944

  Suzuki, Kenji ^a   Iida, Osamu ^b   Soga, Yoshimitsu ^c   Hirano, Keisuke ^d   Inoue, Naoto ^a   Uematsu, Masaaki ^b   Yokoi, Hiroyoshi ^c   Muramatsu, Toshiya ^d   Nanto, Shinsuke ^e   Nobuyoshi, Masakiyo ^c   Meguro, Taiichiro ^a  

^a SENDAI KOUSEI HOSPITAL   (Japan)

^b KANSAI ROSAI HOSPITAL   (Japan)

^c KOKURA MEMORIAL HOSPITAL   (Japan)

^d SAISEIKAI YOKOHAMASHI TOBU HOSPITAL   (Japan)

^e OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Endovascular therapy; S.M.A.R.T. Control stent; Superficial femoral artery

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; NITINOL; TICLOPIDINE;

AGE; AGED; ARTERY LESION; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; HUMAN; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PREDICTION; RETROSPECTIVE STUDY; SEX RATIO; STENT; SUPERFICIAL FEMORAL ARTERY; VASCULAR PATENCY;

AGE FACTORS; AGED; AGED, 80 AND OVER; FEMALE; FEMORAL ARTERY; FOLLOW-UP STUDIES; GRAFT OCCLUSION, VASCULAR; HUMANS; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; REGISTRIES; STENTS; TETRAZOLES; TIME FACTORS; VASODILATOR AGENTS;

EID: 79953663283     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-1029     Document Type: Article

References (21)

1. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326: 381-386.
2. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg 2000; 31: S1-S296.
3. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG; TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 2007; 33(Suppl 1): S1-S75.
4. Kamiya C, Sakamoto S, Tamori Y, Yoshimuta T, Higashi M, Tanaka R, et al. Long-term outcome after percutaneous peripheral intervention vs medical treatment for patients with superficial femoral artery occlusive disease. Circ J 2008; 72: 734-739.
5. Jamieson WR, Janusz MT, Miyaqishima RT, Gerein AN. Influence of ischemic heart disease on early and late mortality after surgery for peripheral occlusive vascular disease. Circulation 1982; 66: 192-197.
6. Gerraty RP, Gates PC, Doyle JC. Carotid stenosis and perioperative stroke risk in symptomatic and asymptomatic patients undergoing vascular or coronary surgery. Stroke 1993; 24: 1115-1118.
7. Rowe VL, Lee W, Weaver FA, Etzioni D. Pattern of treatment for peripheral arterial disease in the United States: 1996-2005. J Vasc Surg 2009; 49: 910-917.
8. Kim SJ, Kim W, Kim JB, Hong MJ, Kang WY, Hwang SH, et al. Determinants of procedural success and patency following subintimal angioplasty in patients with TASC C and D femoropopliteal arterial disease. Circ J 2010; 74: 1959-1964.
9. Cejna M, Thurnher S, Illiasch H, Horvath W, Waldenberger P, Hornik K, et al. PTA versus Palmaz stent placement in femoropopliteal artery obstructions: A multicenter prospective randomized study. J Vasc Interv Radiol 2001; 12: 23-31.
10. Schillinger M, Sabeti S, Loewe C, Dick P, Amighi J, Mlekusch W, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med 2006; 354: 1879-1888.
11. Krankenberg H, Schlüter M, Steinkamp HJ, Bürgelin K, Scheinert D, Schulte KL, et al. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: The femoral artery stenting trial (FAST). Circulation 2007; 116: 285-292.
12. Vorwerk D, Guenther RW, Schürmann K, Wendt G, Peters I. Primary stent placement for chronic iliac artery occlusions: Follow-up results in 103 patients. Radiology 1995; 194: 745-749.
13. Vroegindeweij D, Vos LD, Tielbeek AV, Buth J, vd Bosch HC. Balloon angioplasty combined with primary stenting versus balloon angioplasty alone in femoropopliteal obstructions: A comparative randomized study. Cardiovasc Intervent Radiol 1997; 20: 420-425.
14. Sabeti S, Schillinger M, Amighi J, Sherif C, Mlekusch W, Ahmadi R, et al. Primary patency of femoropopliteal arteries treated with nitinol versus stainless steel self-expanding stents: Propensity scoreadjusted analysis. Radiology 2004; 232: 516-521.
15. Iida O, Nanto S, Uematsu M, Ikeoka K, Okamoto S, Dohi T, et al, Long-term results of endovascular therapy with nitinol stent implantation for TASC II A/B femoro-popliteal artery lesions: 4 years' experience. Circ J 2009; 73: 2143-2147.
16. Dick P, Wallner H, Sabeti S, Loewe C, Mlekusch W, Lammer J, et al. Balloon angioplasty versus stenting with nitinol stents in intermediate length superficial femoral artery lesions. Catheter Cardiovasc Interv 2009; 74: 1090-1095.
17. Iida O, Nanto S, Uematsu M, Morozumi T, Kotani J, Awata M, et al. Cilostazol reduces target lesion revascularization after percutaneous transluminal angioplasty in the femoropopliteal artery. Circ J 2005; 69: 1256-1259.
18. Iida O, Nanto S, Uematsu M, Morozumi T, Kitakaze M, Nagata S. Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions. J Vasc Surg 2008; 48: 144-149.
19. Soga Y, Yokoi H, Kawasaki T, Nakashima H, Tsurugida M, Hikichi Y, et al. Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication. J Am Coll Cardiol 2009; 53: 48-53.
20. Iida O, Nanto S, Uematsu M, Ikeoka K, Okamoto S, Nagata S, et al. Influence of stent fracture on the long-term patency in the femoro-popliteal artery. JACC Cardiovasc Interv 2009; 2: 665-671.
21. Scheinert D, Scheinert S, Sax J, Piorkowski C, Bräunlich S, Ulrich M, et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol 2005; 45: 312-315.